394 related articles for article (PubMed ID: 22894615)
21. New beta-lactamases: a paradigm for the rapid response of bacterial evolution in the clinical setting.
Rossolini GM; Docquier JD
Future Microbiol; 2006 Oct; 1(3):295-308. PubMed ID: 17661642
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and antibacterial resistance patterns of extended-spectrum beta-lactamase producing Gram-negative bacteria isolated from ocular infections.
Rameshkumar G; Ramakrishnan R; Shivkumar C; Meenakshi R; Anitha V; Venugopal Reddy YC; Maneksha V
Indian J Ophthalmol; 2016 Apr; 64(4):303-11. PubMed ID: 27221683
[TBL] [Abstract][Full Text] [Related]
23. New definitions of extended-spectrum β-lactamase conferring worldwide emerging antibiotic resistance.
Lee JH; Bae IK; Lee SH
Med Res Rev; 2012 Jan; 32(1):216-32. PubMed ID: 20577973
[TBL] [Abstract][Full Text] [Related]
24. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams.
Jacoby GA
Infect Dis Clin North Am; 1997 Dec; 11(4):875-87. PubMed ID: 9421705
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
26. Extended-spectrum cephalosporin-resistant Gram-negative organisms in livestock: an emerging problem for human health?
Seiffert SN; Hilty M; Perreten V; Endimiani A
Drug Resist Updat; 2013; 16(1-2):22-45. PubMed ID: 23395305
[TBL] [Abstract][Full Text] [Related]
27. [Appearance of extended-spectrum beta-lactamases].
Iyobe S
Nihon Rinsho; 1997 May; 55(5):1219-24. PubMed ID: 9155178
[TBL] [Abstract][Full Text] [Related]
28. Detection of multi drug resistant bacteria in major hospitals in Kano, North-West, Nigeria.
Yusuf I; Arzai AH; Haruna M; Sharif AA; Getso MI
Braz J Microbiol; 2014; 45(3):791-8. PubMed ID: 25477909
[TBL] [Abstract][Full Text] [Related]
29. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
Walsh TR
Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
[TBL] [Abstract][Full Text] [Related]
30. Are all beta-lactams created equal?
Livermore DM
Scand J Infect Dis Suppl; 1996; 101():33-43. PubMed ID: 9060050
[TBL] [Abstract][Full Text] [Related]
31. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
Giamarellou H
Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
[TBL] [Abstract][Full Text] [Related]
32. Acquired metallo-beta-lactamases: an increasing clinical threat.
Rossolini GM
Clin Infect Dis; 2005 Dec; 41(11):1557-8. PubMed ID: 16267726
[No Abstract] [Full Text] [Related]
33. Systematic research to overcome newly emerged multidrug-resistant bacteria.
Arakawa Y
Microbiol Immunol; 2020 Apr; 64(4):231-251. PubMed ID: 32068266
[TBL] [Abstract][Full Text] [Related]
34. beta-Lactamases of increasing clinical importance.
Bush K
Curr Pharm Des; 1999 Nov; 5(11):839-45. PubMed ID: 10539991
[TBL] [Abstract][Full Text] [Related]
35. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
36. The threat of resistance to the new oral cephalosporins.
Cullmann W
Chemotherapy; 1992; 38 Suppl 2():10-7. PubMed ID: 1516458
[TBL] [Abstract][Full Text] [Related]
37. The current state of multidrug-resistant gram-negative bacilli in North America.
Nicasio AM; Kuti JL; Nicolau DP
Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
[TBL] [Abstract][Full Text] [Related]
38. Evolution of extended-spectrum beta-lactamases by mutation.
Gniadkowski M
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():11-32. PubMed ID: 18154525
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the development of β-lactamase inhibitors.
Jalde SS; Choi HK
J Microbiol; 2020 Aug; 58(8):633-647. PubMed ID: 32720096
[TBL] [Abstract][Full Text] [Related]
40. Fluorescein-labeled beta-lactamase mutant for high-throughput screening of bacterial beta-lactamases against beta-lactam antibiotics.
Chan PH; Chan KC; Liu HB; Chung WH; Leung YC; Wong KY
Anal Chem; 2005 Aug; 77(16):5268-76. PubMed ID: 16097768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
